Showing 1881-1890 of 2494 results for "".
- Prevent Blindness Focus On Eye Health National Summithttps://modernod.com/news/prevent-blindness-focus-on-eye-health-national-summit/2476719/Prevent Blindness will host the 8th Annual Focus on Eye Health National Summit at the National Press Club in Washington DC on Wednesday, July 17 at 7:30 am ET. The theme of the event is “A Lifetime of Vision” and will feature keynote speaker Bill Barkley, deaf-blind adventure
- University of Alberta Scientists Pinpoint a Cause of Pigmentary Glaucomahttps://modernod.com/news/university-of-alberta-scientists-pinpoint-a-cause-of-pigmentary-glaucoma/2476337/An international team of researchers has identified a gene responsible for the onset of pigmentary glaucoma, which may lead to new therapies for the condition. “People who traditionally we wouldn’t think of having glaucoma—young males in their 20s and 30s—are at particular risk
- Eyevance Acquires Global Rights to Persistent Corneal Epithelial Defect Treatment Nexagonhttps://modernod.com/news/eyevance-acquires-global-rights-to-persistent-corneal-epithelial-defect-treatment-nexagon/2479822/Eyevance Pharmaceuticals announced a worldwide licensing agreement with OcuNexus Therapeutics for Nexagon, a 30-base antisense oligomer being developed for the orphan indication of persistent corneal epithelial defect (PED) nonresponsive to standard of care. Terms of the deal were not disc
- First FDA-Approved Iris Prosthesis Now Available in the United Stateshttps://modernod.com/news/veo-ophthalmics-launches-customflex-artificialiris-in-the-united-states/2479835/VEO Ophthalmics announced the launch of the ‘Customflex ArtificialIris,’ the first iris prosthesis available in the United States. The surgically implanted device received FDA approval on May 30, 2018 for use in children and adults for the treatment of iris defects resulting from cong
- REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data From Ongoing Clinical Trialshttps://modernod.com/news/regenxbio-reports-second-quarter-2018-financial-and-operating-results-and-interim-data-from-ongoing-clinical-trials/2479954/REGENXBIO Inc. announced financial results for the quarter ended June 30, 2018, and recent operational highlights including updates to interim data from its ongoing clinical trials. Financial Results Cash, cash equivalents, and marketable securities were $306.3 million as of June
- Blue Light Glasses: Helpful or Just Hype?https://modernod.com/news/blue-light-glasses-helpful-or-just-hype/2477179/Erin Lynn Sattler started worrying when her vision became blurry while using the computer, but her eye doctor said her eyes were fine. Then she got a new computer at work, with a much brighter screen, and her eyes and head started hurting. She’d heard of blue light glasses and did some
- Tenpoint Therapeutics Appoints Stephen S. Lane, MD, as Chief Medical Officerhttps://modernod.com/news/tenpoint-therapeutics-appoints-stephen-s-lane-md-as-chief-medical-officer/2486536/Tenpoint Therapeutics announced the appointment of Stephen S. Lane, MD, as Chief Medical Officer (CMO). In this role, Dr. Lane will join the company’s executive leadership team and oversee clinical development strategy, medical affairs, and pharmacovigilance. <
- AAO: Office-Based Cataract Surgery Study Shows Success With Minimal Oral Sedationhttps://modernod.com/news/aao-office-based-cataract-surgery-study-shows-success-with-minimal-oral-sedation/2484197/A new study presented at the 129th annual meeting of the American Academy of Ophthalmology (AAO) is challenging long-held assumptions about cataract surgery. The research demonstrates that patients can safely and successfully undergo office-based cataract surgery u
- Topcon Healthcare Appoints Daniela Ferrara, MD, PhD, as Chief Medical Officerhttps://modernod.com/news/topcon-healthcare-appoints-daniela-ferrara-md-phd-as-chief-medical-officer/2482764/Topcon Healthcare announced the appointment of Daniela Ferrara, MD, PhD, as its new Chief Medical Officer (CMO). In her new role, Dr. Ferrara will lead Topcon Healthcare’s global medical strategy, overseeing clinical r
- Neurotech Appoints Beth Marsh as Chief Commercial Officerhttps://modernod.com/news/neurotech-appoints-beth-marsh-as-chief-commercial-officer/2482746/Neurotech Pharmaceuticals announced the appointment of Beth Marsh as Chief Commercial Officer, effective April 28, 2025. In this role, Ms. Marsh will lead the commercial organization, including preparing for the US launch of Encelto (revakinagene taroretcel-lwey), the first and onl